SRPT Related Corporate News

Apr 15, 2013 04:12 PM Sarepta (SRPT) Says FDA to Consider Accelerated Approval for Eteplirsen; FDA Would Consider Additional Data

Apr 11, 2013 08:31 AM Sarepta (SRPT), UWA Enter DMD Drug Candidate Development Agreement

Apr 5, 2013 08:32 AM Sarepta Therapeutics (SRPT) Reports Statistically Significant Update on Eteplirsen Phase IIb

Mar 4, 2013 11:07 AM Sarepta (SRPT) Slips Amid Update on Marburg Treatment Candidate, AVI-7288

Jan 30, 2013 05:32 PM Sarepta (SRPT) Issues Comment Following Volatile Stock Activity

Dec 21, 2012 08:31 AM Sarepta (SRPT) Enters CTA with NIAID for AVI-7100 Phase I

Dec 7, 2012 08:35 AM Sarepta (SRPT) Updates on Eteplirsen Study 202; Significant Data Recorded in mITT Population

Nov 26, 2012 08:33 AM Sarepta Therapeutics (SRPT) Enters Agreement to Develop Exon 53-Targeting Drug

Nov 20, 2012 10:28 AM Sarepta (SRPT) Granted New U.S. Patent Covering Antisense Antibacterial Method, Compound

Oct 12, 2012 04:09 PM Sarepta (SRPT) to Update on Additional Eteplirsen Phase IIb Data

Oct 3, 2012 07:08 AM Sarepta (SRPT) Says Eteplirsen Met Primary Endpoint in Phase IIb

Oct 3, 2012 07:07 AM Sarepta (SRPT) Receives Termination Notice from U.S. DoD for Ebola Program

Sep 18, 2012 08:32 AM Sarepta (SRPT) Receives FDA Fast Track Designation for Marburg, Ebola Virus Treatments

Sep 4, 2012 05:07 PM Sarepta Therapeutics (SRPT) Enters $40M At-The-Market Agreement with Citadel

Sep 4, 2012 08:40 AM Sarepta Therapeutics (SRPT) Gets New $3.9M DoD Contract for AVI-7288 Evaluation on IMA

Aug 3, 2012 04:44 PM Sarepta Therapeutics (SPRT) Discloses Stop-Work Order from DoD

Jul 24, 2012 07:16 AM Sarepta Therapeutics (SRPT) Reports Statistically Significant Data for Eteplirsen in DMD Patients

Jul 12, 2012 06:52 AM AVI BioPharma (AVII) (SRPT) Changes Name to 'Sarepta Therapeutics, Inc.'